Yifan Li

China

Dr Li has ertise in management and passion in improving the prognosis and quality of life of patients of gastric cancer.

Member of Shanxi Anti-Cancer Association.

Natalia Neparidze

USA

Dr. Neparidze serves as an Associate Professor and the leader of Yale Myeloma Research team. She has developed multiple research projects in myeloma, including a number of investigator-initiated therapeutic clinical trials. She serves as a PI and co-PI on multiple therapeutic clinical trials and leads several clinical outcomes studies in patients with myeloma. Her ongoing research directions include use of advanced imaging and evaluating tumor heterogeneity to enhance precision medicine approaches for myeloma, novel combination immunotherapy strategies and MRD-driven therapies in myeloma, as well as studying biology and clinical outcomes of monoclonal gammopathies in association with metabolic, viral and other co-morbidities, investigating mechanisms of tumor progression and resistance in myeloma.

Jagadananda Ghosh

USA

Dr. Ghosh is a Senior Scientist at the Henry Ford Hospital in Detroit, Michigan, USA. The primary focus of his research is to understand the mechanisms underlying resistance to anticancer therapies. Recently, his team made a groundbreaking observation that the Tribbles 2 pseudokinase confers resistance to anti-androgens by driving neuroendocrine trans-differentiation. He is keenly interested to explore downstream mechanisms of Tribbles 2 and develop novel agents to overcome therapeutic resistance by targeting Tribbles 2. Dr. Ghosh is an internationally renowned scientist and would like to share recent results related to mechanism-based development of a new therapy for aggressive, drug-resistant, lethal prostate cancer.

Gulcin Ertas

Turkey